1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
LifeTech Scientific Corporation

LifeTech Scientific Corporation

LFTSF
LifeTech Scientific CorporationUS flagOther OTC
0.23
USD
- -
- -
1.03BMarket Cap
LifeTech Scientific Corporation
LFTSF
(Other OTC)

Recent

price

0.23

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.05
0.05
0.05
0.06
0.07
0.08
0.09
0.09
0.13
0.16
0.15
0.21
0.26
0.29
0.3
0.31
0.06
Revenue per Share
- -
- -
0.01
-0.02
-0.02
- -
0.04
0.04
0.03
0.03
0.05
0.07
0.08
0.06
0.05
0.03
-0.02
Basic EPS, GAAP
0.02
- -
0.01
-0.01
-0.01
-0.02
- -
- -
0.02
0.03
0.04
0.02
0.01
0.03
0.01
0.09
- -
Free Cash Flow per Basic Share
0.01
0.01
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
-0.01
- -
-0.02
-0.04
-0.04
-0.01
0.03
0.06
0.13
- -
0.25
0.33
0.38
0.43
0.46
-0.02
Book Value per Share
- -
0.09
0.07
0.05
0.03
0.03
0.19
0.21
0.24
0.22
0.47
0.5
0.59
0.61
0.63
0.62
0.05
Tangible Book Value per Share
1,922
3,052
4,000
4,000
4,000
4,000
4,003
4,325
4,334
4,140
4,338
4,309
4,233
4,356
4,379
4,370
4,000
Basic Weighted Avg Shares
105
140
181
231
283
312
353
409
557
669
642
925
1,097
1,267
1,304
1,370
231
Sales/Revenue/Turnover
32.97
22.2
26.98
20.53
20.03
29.81
28.54
45.78
21.12
17.79
6.4
35.3
31.26
23.24
13.86
12.84
20
Operating Margin (%)
5
6
7
7
7
8
10
17
33
55
63
62
67
77
88
103
- -
Depreciation Expense
4
12
32
-66
-81
2
146
163
121
129
216
292
325
263
222
148
-66
Net Income, GAAP
63.59
34.16
21.16
- -
- -
84.75
22.06
15.52
27.42
25.55
14.67
14.89
15.69
38.78
15.33
41.3
81.44
Effective Tax Rate (%)
3.76
8.43
17.83
-28.42
-28.74
0.76
41.28
39.96
21.75
19.32
33.64
31.61
29.65
20.77
17.06
10.79
-28.42
Profit Margin (%)
-18
237
236
287
322
280
591
450
370
265
1,051
1,355
812
1,461
1,519
846
287
Working Capital
- -
- -
- -
67
78
145
180
- -
22
228
5
5
5
3
1
4
67
LT Debt
3
268
301
236
156
180
871
1,056
1,244
1,162
2,358
2,530
2,921
3,324
3,475
3,475
236
Total Equity
- -
14.52
13.22
- -
- -
4.72
10.65
14.3
7.11
6.18
1.7
10.79
10.41
5.67
4.43
2.93
- -
Return on Invested Capital (%)
- -
-82.77
-191.92
- -
- -
-4.62
234.74
110.61
60.27
24.59
44.01
46.37
26.33
27.64
15.99
9.52
-181.55
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
65.29
32.34
77.84
54.99
26.53
17.31
12.61
7.59
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'13
Sep'13
Dec'13
ST Debt
35
- -
- -
LT Borrowings
63
- -
67
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
4,000
- -
4,000
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Jun'13
Sep'13
Dec'13
Total Current Assets
404
- -
365
Cash, Cash Equivalents & STI
274
- -
225
Accounts Receivable, Net
45
- -
49
Inventories
27
- -
33
Total Current Liabilities
91
- -
77
Payables & Accruals
- -
- -
- -
ST Debt
35
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
55.95%
8.21%
-0.01%
Free Cash Flow
432.15%
182.76%
937.55%
Net Income, GAAP
611.3%
-4.31%
-33.53%
Sales/Revenue/Turnover
16.75%
17.22%
5.07%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
1,267
2024
- -
- -
- -
- -
1,304
2025
- -
- -
- -
- -
1,370

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.06
2024
- -
- -
- -
- -
0.05
2025
- -
- -
- -
- -
0.03

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Xylo Technologies Ltd. (MDGS)
Vycor Medical, Inc. (VYCO)
Positron Corporation (POSC)
LifeTech Scientific Corporation (LFTSF)
Modulight Oyj (MODU.HE)
Acarix AB (publ) (ACIXF)
Business
LifeTech Scientific Corporation (Ticker: LFTSF) is a medical device company primarily engaged in the manufacturing, marketing, and sale of minimally invasive surgical products and medical instruments. Its product portfolio includes advanced stapling devices; surgical staplers and reloads; endoscopic surgical instruments; biologic and synthetic surgical meshes; hernia repair products; and wound closure technology. LifeTech also provides comprehensive solutions in laparoscopic and thoracic surgery tools, covering multiple surgical specialties. The company operates globally, serving hospitals and surgery centers across key international markets, with headquarters located in China. In the past 1-2 years, LifeTech has notably expanded its product offerings by launching new surgical staplers and enhanced minimally invasive surgical solutions designed to improve procedural efficiency and patient outcomes. The company has also pursued strategic partnerships to strengthen its distribution network and accelerate innovation in surgical technologies. Key operational changes include increased investment in research and development, as well as an expansion of its direct sales force to better serve diverse geographic markets. These efforts underscore LifeTech’s commitment to maintaining a leading position in the global medical technology sector. Founded in 2003, LifeTech Scientific Corporation operates primarily within the medical devices and healthcare industries, targeting surgeons, hospitals, and healthcare providers that require advanced surgical equipment. The company also manages subsidiary entities that specialize in specific product lines and regional sales operations, enhancing its market reach and operational efficiency. Overall, LifeTech Scientific Corporation offers a comprehensive suite of surgical products and technologies that support minimally invasive surgery, wound management, and hernia repair, backed by ongoing innovations and strategic growth activities to sustain its competitive edge in the global medical devices market.